Evidence map›Paper›PMID 29372390›Full record

Observational studyJournal of neurology2018

Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients.

Tomohisa Nezu, Takaya Kitano, Satoshi Kubo, Junichi Uemura, Shinji Yamashita, Takeshi Iwanaga, Takeshi Inoue, Naohisa Hosomi, Hirofumi Maruyama, Masayasu Matsumoto and 2 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05907694 (Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05907694 narecruitingnot on this mapstarted 2024, after this paper: background citation

Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial

TypeinterventionalSponsorJosep Rodes-CabauRan2024 to 2037Enrolled714ConditionsPatent Foramen Ovale, Cryptogenic Stroke, Older Patients, Medical TreatmentArmsTranscatheter PFO closure, Optimal medical treatment
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Tomohisa NezuDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan. tomonezu@hiroshima-u.ac.jp.
Takaya KitanoDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Satoshi KuboDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Junichi UemuraDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Shinji YamashitaDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Takeshi IwanagaDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Takeshi InoueDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Naohisa HosomiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hirofumi MaruyamaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Masayasu MatsumotoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Kazumi KimuraDepartment of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Yoshiki YagitaDepartment of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
Kawasaki Medical School · JPHiroshima University · JPJapan Community Healthcare Organization · JPNippon Medical School · JP

Funding

JSPS KAKENHI 17K17907
6 · The paper itself

Abstract

backgroundD-dimer levels are used in several clinical settings, such as in predicting venous thrombosis, cardioembolic stroke and cancer status. In the present study, we investigated the associations between plasma D-dimer levels at admission, clinical characteristics and mortality at discharge in cryptogenic stroke patients. We also investigated whether D-dimer levels can predict long-term outcomes in those patients, including those with and without right-to-left shunt (RLS).

methodsAcute cryptogenic stroke patients (n = 295, 72 ± 13 years old) were consecutively enrolled and retrospectively analyzed. We defined the cryptogenic stroke as an undetermined etiology according to the Trial of Org 10172 in Acute Stroke Treatment criteria. Plasma D-dimer levels at admission were evaluated. Assessments for RLS were performed using saline contrast-transcranial Doppler ultrasonography or contrast-transesophageal echography. Survivors (at discharge) underwent follow-up for up to 3 years after stroke onset.

resultsOf the total enrolled cohort, 17 patients died at discharge. D-dimer levels correlated with initial National Institutes of Health Stroke Scale (NIHSS) score (r = 0.391, P < 0.001) and were associated with mortality at discharge [odds ratio 1.04; 95% confidence interval (CI) 1.00-1.08, P = 0.049] after adjusting for age, sex and initial NIHSS score. Of the 278 survivors at discharge, 266 patients were evaluated to assess RLS during hospitalization, and 62 patients (23.3%) exhibited RLS. According to the median plasma D-dimer levels at admission (0.7 µg/ml), the patients were divided into a low D-dimer group (n = 136, < median) and a high D-dimer group (n = 130, ≥ median). Patients in the high D-dimer group were older, more frequently female, had a lower BMI, had a higher prevalence of cancer and had greater initial neurological severity compared to the patients in the low D-dimer group. During the follow-up period (median, 1093 days), 31 patients developed recurrent stroke and 33 patients died. High D-dimer levels at admission were independently associated with recurrent stroke and all-cause mortality [hazard ratio (HR) 3.76; 95% CI 1.21-14.1, P = 0.021) in patients with RLS, but not in those without RLS (HR 1.35; 95% CI 0.74-2.50, P = 0.335).

conclusionsIncreased D-dimer levels at admission were associated with mortality at discharge in cryptogenic stroke patients. In addition, high D-dimer levels were also associated with long-term outcomes in cryptogenic stroke patients with RLS.

Indexed as

AgedBiomarkersChemical Hazard ReleaseFemaleFibrin Fibrinogen Degradation ProductsFollow-Up StudiesHumansKaplan-Meier EstimateMalePrognosisRecurrenceRetrospective StudiesSeverity of Illness IndexStrokeBiomarkersFibrin Fibrinogen Degradation Productsfibrin fragment DCryptogenic strokeD-dimerOutcome

Identifiers

PMID29372390
OpenAlexW2784539044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.